Items tagged with Treatment
Drug-resistant TB: Does moxifloxacin prolong QT interval? (post)
Moxifloxacin, when used as part of a shorter treatment regimen for drug-resistant tuberculosis (DR-TB), appears not to increase the risk for prolonging the QT interval (ie, interval between heart contraction and relaxation — the Q through T waves seen on electrocardiogram). This was among study results recently published in the Journal of Clinical Tuberculosis and other Mycobacterial Diseases.
Effect of diabetes on rifampicin levels in patients with TB (post)
Patients with diabetes mellitus (DM) and tuberculosis (TB) had a significantly higher incidence of low rifampicin plasma levels 2 hours after the anti-tubercular drug was administered, compared with patients with TB who did not have DM, according to results of a systematic review and meta-analysis recently published in the journal Therapies.
ICMR study to assess efficacy of 4-month TB treatment regimen underway (post)
Chennai, Jul 4: ICMR’s National Institute for Research in Tuberculosis has initiated a study to assess the efficacy of a four-month tuberculosis treatment regimen as compared to the existing six-month regimen.
5 things to know about the new 4-month TB treatment regimen (post)
On February 24, 2022, the Centers for Disease Control and Prevention (CDC) published new interim guidance in Morbidity and Mortality Weekly Report on a 4-month treatment regimen as an option for US patients with drug-susceptible pulmonary tuberculosis (TB).[1] The 4-month treatment regimen consists of high-dose daily rifapentine with moxifloxacin, isoniazid, and pyrazinamide. Shorter regimens help patients complete treatment faster.
TB patients at increased risk of all-cause mortality even after treatment: ICMR (post)
The studies followed up 4,022 TB patients and 12,243 gender-matched and age-matched controls for their long term survival. Even though TB patients were treated successfully, the long-term follow-up of individuals treated for TB showed that there was an excess of premature deaths among those affected by the disease, the key findings stated.
Kenya unveils latest innovations to diagnose and treat TB (post)
-- Some of the new tools introduced include eight ultra-portable digital chest X-ray machines that are battery-operated.
-- The machines emit lower doses of radiation and can be packed into backpacks and so easily transported into the field.
Dolutegravir twice-daily dosing in children with HIV-associated TB: a pharmacokinetic and safety study within the open-label, multicentre, randomised, non-inferiority ODYSSEY trial (post)
Children with HIV-associated TB have few antiretroviral therapy options. A study, published in The Lancet HIV, evaluated the safety and pharmacokinetics of dolutegravir twice-daily dosing in children receiving rifampicin for HIV-associated TB.
The IJTLD Clinical Standards for Lung Health (post)
The International Journal of Tuberculosis and Lung Disease (IJTLD) published the first four Clinical Standards for Lung Health.
Oral six-month treatment for MDR-TB is safe and effective in people with HIV (post)
An all-oral treatment regimen for multidrug-resistant tuberculosis (MDR-TB) recently recommended as a new standard of care by the World Health Organization is effective and safe in people living with HIV, Dr Ilaria Motta of Médecins sans Frontières reported at the 24th International AIDS Conference (AIDS 2022) in Montreal.
Scientists create long-acting injectable drug delivery system for TB (post)
Led by Martina Kovarova, PhD, Miriam Braunstein, PhD, and J. Victor Garcia, PhD, UNC School of Medicine researchers showed in vivo efficacy of a long-acting injectable formulation of the anti-TB drug rifabutin.
Page 65 of 108 · Total posts: 0
←First 64 65 66 Last→